8 Drug Manufacturers - General companies within the Healthcare sector.
| Symbol | Company | Price | 1‑day | 1‑month |
|---|---|---|---|---|
| LLY | Eli Lilly | $1,186 | -0.52% | -2.57% |
| JNJ | Johnson & Johnson | $259.24 | +0.88% | +0.05% |
| ABBV | AbbVie | $246.04 | +0.89% | -0.85% |
| MRK | Merck | $128.58 | +0.16% | +2.81% |
| AMGN | Amgen | $410.95 | +1.51% | +13.02% |
| GILD | Gilead Sciences | $133.21 | +1.80% | -1.21% |
| PFE | Pfizer | $26.76 | +2.14% | +12.28% |
| BIIB | Biogen | $207.94 | +0.80% | +4.54% |
Large pharmaceutical companies are highly profitable businesses with a scheduled problem. Patents on their major products expire on known dates, and when they do, generic competition removes the great majority of that product's revenue within a couple of years. Every one of these companies is therefore running a race to replace revenue it already knows it will lose.
That race is run through internal research and through acquisition, and the balance between the two tells you a lot about how a management team rates its own pipeline. Because the expiry dates are public, the useful analysis is not whether a cliff is coming but whether what is behind it is large enough and close enough to approval to matter.
Want a full fundamental breakdown on one of these companies?
Generate a free reportPrices shown are end-of-session closing values from the most recent completed trading day and are refreshed periodically, not in real time. Sector and industry classifications follow the labels reported by our market data provider and can differ from other schemes. This page is informational and is not investment advice.